한올바이오파마

009420KOSPI의약품 제조업

43.9 / 100

Reference Date: 2026-07-24

Financial Score10.0 / 40

News Sentiment17.9 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Plunged 15.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanall BioPharma, established in 1973, focuses on R&D, manufacturing, and sales of synthetic and biopharmaceuticals, with a particular emphasis on developing new drugs for autoimmune diseases, eye conditions, cancer, and neurological disorders. In 2024, the company reported revenue of 138.9 billion KRW, with its subsidiary HPI handling overseas clinical trials and licensing activities.

Number of Employees

315people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

16.04Industry Average 0.810.0Point

19.8x industry avg (risky)

ROE

-3.37Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

11.80Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼293.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.8% (declining, 3yr)

Detailed News Sentiment

10 totalPositive 6Neutral 3Negative 1Average Sentiment Score 71.5

Negative
한올바이오파마, '바토클리맙' 中사업권 회수 불발
한올바이오파마의 중국 내 '바토클리맙' 라이선스 계약 해지 시도가 국제상업회의소에 의해 무효로 판정되어 부정적 영향 예상.
Neutral
[실전재테크]'부진' 제약·바이오주, 언제 오를까
Overall market sentiment towards Korean biotech stocks remains cautious despite hopes for recovery in the second half.
Positive
제약·바이오 하반기 '이벤트 장세' 열린다
하반기 제약·바이오 분야의 주요 이벤트로 한올바이오파마를 포함한 여러 기업들의 성과 발표가 기대되어 기업 가치 재평가가 예상됩니다.

Detailed Momentum

52-week position5.0Point

52w mid range (53%)

Current 49,650Won52-week high 70,70052-week low 25,700

1-month return0.0Point

1m -15.27% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]투자판단관련주요경영사항2026-07-22
Neutral투자판단관련주요경영사항2026-07-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02
Neutral주식등의대량보유상황보고서(약식)2026-07-01
Neutral지속가능경영보고서등관련사항(자율공시)2026-06-30